Hyderabad-based GVK Biosciences, which offers R&D services in clinical sciences connecting chemistry, biology and informatics, today said that the US Food & Drug Administration has extended the licence that allows it access to its clinical biomarker database (Gobiom) by another year.
The Gobiom database contains updated information on all the biomarkers reported in various clinical and preclinical studies. The US drug regulator uses the database in its biomarker qualification process. The licence and its extension involves a financial transaction, but the company declined to disclose the details.
According to Sreeni Devidas, vice president (sales & marketing), Informatics, GVK Bio, collaboration with the USFDA helped GVK Bio develop the safety biomarker content in Gobiom. He said its biomarker analysis tools were integrated into the database so that users can make comparative analysis between the biomarkers of their interest.
GVK Bio has over 150 customers from across the world including companies operating in pharmaceutical, biotechnology, agro, life-sciences space, apart from academic institutions.